ZFP64
geneOn this page
Also known as FLJ10734dJ831D17.1FLJ12628dJ548G19.1
Summary
ZFP64 (ZFP64 zinc finger protein, HGNC:15940) is a protein-coding gene on chromosome 20q13.2, encoding Zinc finger protein 64 (Q9NTW7). May be involved in the regulation of mesenchymal cell differentiation through transactivation of NOTCH1 target genes.
Predicted to enable DNA binding activity and zinc ion binding activity. Involved in mesenchymal cell differentiation. Located in cytoplasm and megasporocyte nucleus.
Source: NCBI Gene 55734 — RefSeq curated summary.
At a glance
- GWAS associations: 21
- Clinical variants (ClinVar): 158 total
- MANE Select transcript:
NM_018197
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:15940 |
| Approved symbol | ZFP64 |
| Name | ZFP64 zinc finger protein |
| Location | 20q13.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ10734, dJ831D17.1, FLJ12628, dJ548G19.1 |
| Ensembl gene | ENSG00000020256 |
| Ensembl biotype | protein_coding |
| OMIM | 618111 |
| Entrez | 55734 |
Gene structure
Transcript identifiers
Ensembl transcripts: 14 — 11 protein_coding, 3 protein_coding_CDS_not_defined
ENST00000216923, ENST00000346617, ENST00000361387, ENST00000371515, ENST00000371518, ENST00000371523, ENST00000395979, ENST00000395989, ENST00000456175, ENST00000461898, ENST00000467811, ENST00000477786, ENST00000904902, ENST00000959945
RefSeq mRNA: 5 — MANE Select: NM_018197
NM_001319146, NM_018197, NM_022088, NM_199426, NM_199427
CCDS: CCDS13439, CCDS13440, CCDS13441, CCDS13442, CCDS82630
Canonical transcript exons
ENST00000216923 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001455405 | 52151278 | 52153428 |
| ENSE00001455426 | 52191591 | 52191779 |
| ENSE00003480273 | 52165864 | 52166025 |
| ENSE00003523171 | 52160123 | 52160374 |
| ENSE00003647271 | 52186832 | 52187071 |
| ENSE00003659006 | 52164695 | 52164757 |
Expression profiles
Bgee: expression breadth ubiquitous, 288 present calls, max score 93.02.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.5957 / max 127.4062, expressed in 1755 samples.
FANTOM5 promoters (12 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 187985 | 9.7981 | 1739 |
| 187978 | 1.9356 | 777 |
| 187987 | 1.4111 | 789 |
| 187984 | 0.7342 | 509 |
| 187986 | 0.2277 | 101 |
| 187977 | 0.1231 | 45 |
| 187980 | 0.1230 | 58 |
| 187979 | 0.0932 | 37 |
| 187988 | 0.0898 | 40 |
| 187982 | 0.0386 | 8 |
Top tissues by expression
290 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| germinal epithelium of ovary | UBERON:0001304 | 93.02 | gold quality |
| gingival epithelium | UBERON:0001949 | 92.93 | gold quality |
| secondary oocyte | CL:0000655 | 91.93 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 91.32 | gold quality |
| gingiva | UBERON:0001828 | 90.89 | gold quality |
| parietal pleura | UBERON:0002400 | 90.60 | gold quality |
| pleura | UBERON:0000977 | 89.84 | gold quality |
| oocyte | CL:0000023 | 89.61 | gold quality |
| squamous epithelium | UBERON:0006914 | 89.51 | gold quality |
| endothelial cell | CL:0000115 | 89.32 | gold quality |
| visceral pleura | UBERON:0002401 | 89.29 | gold quality |
| hair follicle | UBERON:0002073 | 89.11 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 88.88 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 88.85 | gold quality |
| cervix squamous epithelium | UBERON:0006922 | 87.96 | gold quality |
| mammary duct | UBERON:0001765 | 87.93 | gold quality |
| epithelium of mammary gland | UBERON:0003244 | 87.92 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 87.88 | gold quality |
| tibia | UBERON:0000979 | 87.30 | gold quality |
| bronchial epithelial cell | CL:0002328 | 87.18 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 87.13 | gold quality |
| penis | UBERON:0000989 | 87.12 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 86.89 | gold quality |
| nasopharynx | UBERON:0001728 | 86.88 | gold quality |
| colonic mucosa | UBERON:0000317 | 86.81 | gold quality |
| metanephric glomerulus | UBERON:0004736 | 86.56 | gold quality |
| renal glomerulus | UBERON:0000074 | 86.33 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 86.12 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 86.06 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 86.02 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 5.31 |
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
5 targets.
| Target | Regulation |
|---|---|
| CDKN2A | |
| IFNB1 | Repression |
| IL6 | Repression |
| NOTCH1 | |
| TNF | Activation |
Upstream regulators (CollecTRI, top): RUNX2
miRNA regulators (miRDB)
53 targeting ZFP64, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-MIR-371B-5P | 99.99 | 75.34 | 4759 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-373-5P | 99.98 | 75.36 | 4753 |
| HSA-MIR-616-5P | 99.98 | 75.58 | 4775 |
| HSA-MIR-568 | 99.98 | 69.86 | 2084 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-380-3P | 99.89 | 70.18 | 1978 |
| HSA-MIR-153-5P | 99.89 | 73.86 | 6317 |
| HSA-MIR-6780A-5P | 99.88 | 66.69 | 2776 |
| HSA-MIR-4728-5P | 99.85 | 69.39 | 4718 |
| HSA-MIR-3180-5P | 99.82 | 69.12 | 2422 |
| HSA-MIR-6785-5P | 99.82 | 68.68 | 4428 |
| HSA-MIR-1273H-5P | 99.77 | 66.32 | 2471 |
| HSA-MIR-30B-3P | 99.70 | 65.76 | 2325 |
| HSA-MIR-3689A-3P | 99.70 | 65.73 | 2306 |
| HSA-MIR-3689B-3P | 99.70 | 65.71 | 2311 |
| HSA-MIR-3689C | 99.70 | 65.71 | 2311 |
| HSA-MIR-6779-5P | 99.70 | 65.76 | 2363 |
| HSA-MIR-1303 | 99.65 | 69.77 | 1662 |
| HSA-MIR-10393-5P | 99.65 | 68.01 | 1368 |
| HSA-MIR-5700 | 99.64 | 69.88 | 2280 |
| HSA-MIR-6848-3P | 99.64 | 66.49 | 885 |
| HSA-MIR-4261 | 99.59 | 70.30 | 3415 |
| HSA-MIR-7106-5P | 99.53 | 67.47 | 3574 |
Literature-anchored findings (GeneRIF, showing 4)
- Data indicate zinc finger protein 64 (ZFP64) as an essential transcription factor in mixed-lineage leukemia protein (MLL)-rearranged leukemia. (PMID:30503706)
- Function and mechanism exploration of zinc finger protein 64 in lung adenocarcinoma cell growth and metastasis. (PMID:33054540)
- ZFP64::NCOA3 gene fusion defines a novel subset of spindle cell rhabdomyosarcoma. (PMID:35521817)
- ZFP64 transcriptionally activates PD-1 and CTLA-4 and plays an oncogenic role in esophageal cancer. (PMID:35843097)
Cross-species orthologs
12 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | zfp64 | ENSDARG00000061147 |
| mus_musculus | Zfp64 | ENSMUSG00000027551 |
| rattus_norvegicus | Zfp93 | ENSRNOG00000012762 |
| drosophila_melanogaster | wek | FBGN0001990 |
| drosophila_melanogaster | kmg | FBGN0032473 |
| drosophila_melanogaster | CG17568 | FBGN0032763 |
| drosophila_melanogaster | CG10366 | FBGN0032814 |
| drosophila_melanogaster | CG8388 | FBGN0034062 |
| drosophila_melanogaster | CG4282 | FBGN0034114 |
| drosophila_melanogaster | CG4707 | FBGN0035036 |
| drosophila_melanogaster | CG6254 | FBGN0037794 |
| drosophila_melanogaster | CG9932 | FBGN0262160 |
Paralogs (1): ZNF335 (ENSG00000198026)
Protein
Protein identifiers
Zinc finger protein 64 — Q9NTW7 (reviewed: Q9NTW7)
Alternative names: Zinc finger protein 338
All UniProt accessions (4): A2A2N5, A2A2N6, Q9NTW7, H0Y669
UniProt curated annotations — full annotation on UniProt →
Function. May be involved in the regulation of mesenchymal cell differentiation through transactivation of NOTCH1 target genes.
Subunit / interactions. Interacts with ZNF70; this interaction promote the transactivation of the HES1 gene. Interacts with NOTCH1.
Subcellular location. Nucleus.
Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.
Isoforms (6)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9NTW7-1 | 3 | yes |
| Q9NTW7-2 | 4, ZNF338 | |
| Q9NTW7-3 | 5 | |
| Q9NTW7-4 | 6 | |
| Q9NTW7-5 | 1 | |
| Q9NTW7-6 | 2 |
RefSeq proteins (5): NP_001306075, NP_060667, NP_071371, NP_955458, NP_955459 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR013087 | Znf_C2H2_type | Domain |
| IPR036236 | Znf_C2H2_sf | Homologous_superfamily |
| IPR050636 | C2H2-ZF_domain-containing | Family |
Pfam: PF00096
UniProt features (57 total): zinc finger region 13, strand 11, splice variant 8, helix 7, sequence variant 6, compositionally biased region 3, region of interest 2, sequence conflict 2, cross-link 2, chain 1, turn 1, modified residue 1
Structure
Experimental structures (PDB)
2 structures.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 1X5W | SOLUTION NMR | |
| 2DMD | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9NTW7-F1 | 64.78 | 0.01 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (3): 545, 286, 397
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 124 (showing top):
MITSIADES_RESPONSE_TO_APLIDIN_DN, GOBP_MESENCHYMAL_CELL_DIFFERENTIATION, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, GOBP_MESENCHYME_DEVELOPMENT, MCCLUNG_COCAINE_REWARD_5D, JACKSON_DNMT1_TARGETS_UP, VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_UP, SANSOM_APC_MYC_TARGETS, SCGGAAGY_ELK1_02, KIM_WT1_TARGETS_DN, MGGAAGTG_GABP_B, NIKOLSKY_MUTATED_AND_AMPLIFIED_IN_BREAST_CANCER, NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN
GO Biological Process (3): positive regulation of transcription by RNA polymerase II (GO:0045944), mesenchymal cell differentiation (GO:0048762), regulation of gene expression (GO:0010468)
GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), megasporocyte nucleus (GO:0043076)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of transcription by RNA polymerase II | 1 |
| transcription by RNA polymerase II | 1 |
| positive regulation of DNA-templated transcription | 1 |
| cell differentiation | 1 |
| mesenchyme development | 1 |
| gene expression | 1 |
| regulation of macromolecule biosynthetic process | 1 |
| nucleic acid binding | 1 |
| transition metal ion binding | 1 |
| binding | 1 |
| cation binding | 1 |
| intracellular membrane-bounded organelle | 1 |
| intracellular anatomical structure | 1 |
| cellular anatomical structure | 1 |
| nucleus | 1 |
Protein interactions and networks
STRING
1008 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZFP64 | TRPS1 | Q9UHF7 | 556 |
| ZFP64 | RUNX3 | Q13761 | 544 |
| ZFP64 | NOTCH1 | P46531 | 504 |
| ZFP64 | MMP13 | P45452 | 425 |
| ZFP64 | TMEM240 | Q5SV17 | 419 |
| ZFP64 | SIK3 | Q9Y2K2 | 407 |
| ZFP64 | CFAP20DC | Q6ZVT6 | 400 |
| ZFP64 | TSHZ2 | Q9NRE2 | 400 |
| ZFP64 | BCAS4 | Q8TDM0 | 397 |
| ZFP64 | SEC16B | Q96JE7 | 397 |
| ZFP64 | IHH | Q14623 | 396 |
| ZFP64 | KRTAP19-7 | Q3SYF9 | 396 |
| ZFP64 | PLEKHN1 | Q494U1 | 396 |
| ZFP64 | SPP1 | P10451 | 390 |
| ZFP64 | TMEM18 | Q96B42 | 388 |
IntAct
102 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| ZFP64 | FHL2 | psi-mi:“MI:0915”(physical association) | 0.740 |
| FHL2 | ZFP64 | psi-mi:“MI:0915”(physical association) | 0.740 |
| ZFP64 | LNX1 | psi-mi:“MI:0915”(physical association) | 0.670 |
| AEN | ZFP64 | psi-mi:“MI:0915”(physical association) | 0.670 |
| ZFP64 | AEN | psi-mi:“MI:0915”(physical association) | 0.670 |
| ZFP64 | TRIM41 | psi-mi:“MI:0915”(physical association) | 0.670 |
| TRIM41 | ZFP64 | psi-mi:“MI:0915”(physical association) | 0.670 |
| LNX1 | ZFP64 | psi-mi:“MI:0915”(physical association) | 0.670 |
| LMO2 | ZFP64 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZFP64 | MFAP1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZFP64 | BYSL | psi-mi:“MI:0915”(physical association) | 0.560 |
| BYSL | ZFP64 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (71): ZFP64 (Two-hybrid), ZFP64 (Two-hybrid), ZFP64 (Two-hybrid), ZFP64 (Two-hybrid), PBK (Two-hybrid), AEN (Two-hybrid), LNX1 (Two-hybrid), TRIM41 (Two-hybrid), FAM124A (Two-hybrid), ZFP64 (Affinity Capture-MS), ZFP64 (Two-hybrid), BEGAIN (Two-hybrid), AEN (Two-hybrid), TRIM41 (Two-hybrid), ZFP64 (Affinity Capture-MS)
ESM2 similar proteins: A1L1J6, B1H2Q6, G5E8B9, O08954, O43167, O43623, O43829, O62836, O95625, P08044, P08048, P08155, P10925, P15619, P17010, P17012, P20385, P20662, P60319, P97469, Q01611, Q08376, Q13105, Q17895, Q20082, Q22024, Q25C93, Q3MHQ4, Q3U3I9, Q52V16, Q5DU09, Q5SVQ8, Q60821, Q6B4Z5, Q804Q5, Q811F1, Q8I7Z8, Q8N9L1, Q8TF68, Q90625
Diamond homologs: A0A1V6NWD3, A1L2U9, B0X9H6, B0XS89, B1WAZ8, B1WBU4, C8VJW0, G5EBU4, J9VX63, O60315, P10925, P15822, P20662, P31629, P36197, P52739, P53243, P56270, P56670, P56671, P78871, P80944, Q00453, Q00900, Q01611, Q03172, Q0IH98, Q0VCJ6, Q12132, Q29419, Q2I689, Q3UHF7, Q4WXK4, Q5JPB2, Q5RAU9, Q60542, Q62947, Q64318, Q6IQX8, Q6P882
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
158 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 139 |
| Likely benign | 3 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1997 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 20:52088386:ACTC:A | donor_loss | 1.0000 |
| 20:52088387:CTCA:C | donor_loss | 1.0000 |
| 20:52088388:TCACC:T | donor_loss | 1.0000 |
| 20:52088389:CACCC:C | donor_loss | 1.0000 |
| 20:52088390:A:AC | donor_gain | 1.0000 |
| 20:52088390:AC:A | donor_gain | 1.0000 |
| 20:52088391:C:CA | donor_loss | 1.0000 |
| 20:52088391:C:CC | donor_gain | 1.0000 |
| 20:52088391:CC:C | donor_gain | 1.0000 |
| 20:52088391:CCCG:C | donor_gain | 1.0000 |
| 20:52088391:CCCGT:C | donor_gain | 1.0000 |
| 20:52088654:A:C | acceptor_gain | 1.0000 |
| 20:52097368:CCTA:C | donor_loss | 1.0000 |
| 20:52097369:CTA:C | donor_loss | 1.0000 |
| 20:52097370:TA:T | donor_loss | 1.0000 |
| 20:52097371:A:AC | donor_gain | 1.0000 |
| 20:52097371:AC:A | donor_gain | 1.0000 |
| 20:52097372:C:CC | donor_gain | 1.0000 |
| 20:52097372:CC:C | donor_gain | 1.0000 |
| 20:52097432:CAAC:C | acceptor_gain | 1.0000 |
| 20:52097435:CCTAG:C | acceptor_loss | 1.0000 |
| 20:52097436:C:CA | acceptor_loss | 1.0000 |
| 20:52097436:C:CC | acceptor_gain | 1.0000 |
| 20:52097437:T:A | acceptor_loss | 1.0000 |
| 20:52098432:TCTTA:T | donor_loss | 1.0000 |
| 20:52098433:CTTAC:C | donor_loss | 1.0000 |
| 20:52098434:TTACC:T | donor_loss | 1.0000 |
| 20:52098435:TA:T | donor_loss | 1.0000 |
| 20:52098436:A:T | donor_loss | 1.0000 |
| 20:52098437:C:CG | donor_loss | 1.0000 |
AlphaMissense
4532 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 20:52160149:A:G | L246P | 1.000 |
| 20:52160180:A:G | C236R | 1.000 |
| 20:52160189:A:G | C233R | 1.000 |
| 20:52160223:G:C | H221Q | 1.000 |
| 20:52160223:G:T | H221Q | 1.000 |
| 20:52160225:G:C | H221D | 1.000 |
| 20:52160233:A:G | L218P | 1.000 |
| 20:52160273:A:G | C205R | 1.000 |
| 20:52160307:G:C | H193Q | 1.000 |
| 20:52160307:G:T | H193Q | 1.000 |
| 20:52160309:G:C | H193D | 1.000 |
| 20:52160334:A:C | F184L | 1.000 |
| 20:52160334:A:T | F184L | 1.000 |
| 20:52160336:A:G | F184L | 1.000 |
| 20:52160348:A:G | C180R | 1.000 |
| 20:52160357:A:G | C177R | 1.000 |
| 20:52164699:G:C | H169Q | 1.000 |
| 20:52164699:G:T | H169Q | 1.000 |
| 20:52164701:G:C | H169D | 1.000 |
| 20:52164711:A:C | H165Q | 1.000 |
| 20:52164711:A:T | H165Q | 1.000 |
| 20:52164713:G:C | H165D | 1.000 |
| 20:52164713:G:T | H165N | 1.000 |
| 20:52160137:A:G | L250P | 0.999 |
| 20:52160139:G:C | H249Q | 0.999 |
| 20:52160139:G:T | H249Q | 0.999 |
| 20:52160141:G:C | H249D | 0.999 |
| 20:52160141:G:T | H249N | 0.999 |
| 20:52160166:G:C | S240R | 0.999 |
| 20:52160166:G:T | S240R | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000010681 (20:52101852 C>T), RS1000062976 (20:52101717 T>A,G), RS1000125947 (20:52189437 CAGATCAT>C), RS1000133287 (20:52105670 C>G,T), RS1000136706 (20:52187860 C>T), RS1000197566 (20:52189208 G>A,C), RS1000199441 (20:52106967 G>A), RS1000206153 (20:52123466 C>G,T), RS1000225255 (20:52166796 G>T), RS1000267493 (20:52087911 G>A,C,T), RS1000285181 (20:52161258 T>C,G), RS1000327867 (20:52155936 C>G,T), RS1000369339 (20:52154591 A>T), RS1000401058 (20:52161072 G>A), RS1000403085 (20:52156164 C>T)
Disease associations
OMIM: gene MIM:618111 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
21 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST000013_5 | Amyotrophic lateral sclerosis | 5.000000e-06 |
| GCST001521_14 | Subcutaneous adipose tissue | 5.000000e-06 |
| GCST002783_119 | Body mass index | 2.000000e-11 |
| GCST002783_144 | Body mass index | 8.000000e-08 |
| GCST002783_331 | Body mass index | 2.000000e-08 |
| GCST003059_22 | Parkinson’s disease | 1.000000e-06 |
| GCST004064_29 | Waist-hip ratio | 2.000000e-08 |
| GCST004064_32 | Waist-hip ratio | 9.000000e-06 |
| GCST004065_104 | Waist circumference | 1.000000e-08 |
| GCST004065_90 | Waist circumference | 2.000000e-09 |
| GCST004068_18 | Venous thromboembolism adjusted for sickle cell variant rs77121243-T | 8.000000e-06 |
| GCST004401_7 | Reading disability or specific language impairment (pleiotropy) | 6.000000e-06 |
| GCST004495_87 | BMI (adjusted for smoking behaviour) | 1.000000e-06 |
| GCST004497_65 | Body mass index (joint analysis main effects and smoking interaction) | 3.000000e-06 |
| GCST004499_80 | BMI in non-smokers | 4.000000e-06 |
| GCST004904_208 | Body mass index | 5.000000e-13 |
| GCST005651_9 | Urinary metabolite levels in chronic kidney disease | 3.000000e-08 |
| GCST005830_60 | Hand grip strength | 2.000000e-08 |
| GCST010242_256 | HDL cholesterol levels | 1.000000e-09 |
| GCST010988_328 | Adult body size | 3.000000e-19 |
| GCST90000025_690 | Appendicular lean mass | 5.000000e-13 |
EFO canonical traits (7, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004340 | body mass index |
| EFO:0004343 | waist-hip ratio |
| EFO:0004318 | smoking behavior |
| EFO:0005116 | urinary metabolite measurement |
| EFO:0006941 | grip strength measurement |
| EFO:0004612 | high density lipoprotein cholesterol measurement |
| EFO:0004980 | appendicular lean mass |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
33 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | decreases expression, affects methylation | 3 |
| Valproic Acid | increases expression, affects expression, decreases expression | 3 |
| Tretinoin | decreases expression | 2 |
| TAK-243 | increases sumoylation | 1 |
| dicrotophos | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| beta-lapachone | decreases expression | 1 |
| sodium arsenite | affects cotreatment, increases abundance, increases expression | 1 |
| manganese chloride | affects cotreatment, increases abundance, increases expression | 1 |
| benzo(e)pyrene | increases methylation | 1 |
| aflatoxin B2 | affects methylation | 1 |
| N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| entinostat | increases expression | 1 |
| abrine | decreases expression | 1 |
| bisphenol S | decreases methylation | 1 |
| jinfukang | affects cotreatment, increases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| Sunitinib | increases expression | 1 |
| Vorinostat | decreases expression | 1 |
| Air Pollutants | affects expression, increases abundance | 1 |
| Arsenic | affects cotreatment, increases abundance, increases expression | 1 |
| Azacitidine | affects methylation | 1 |
| Cisplatin | increases expression, affects cotreatment | 1 |
| Doxorubicin | decreases expression | 1 |
| Manganese | affects cotreatment, increases abundance, increases expression | 1 |
| Methapyrilene | increases methylation | 1 |
| Ozone | increases abundance, affects expression | 1 |
| Phthalic Acids | decreases methylation | 1 |
| Tobacco Smoke Pollution | decreases expression | 1 |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_HD08 | HEK293 eGFP-ZFP64 | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): amyotrophic lateral sclerosis, dyslexia, Parkinson disease, specific language impairment, venous thromboembolism